IFIT1 Inhibitors
IFIT1 inhibitors represent a diverse class of chemicals with distinct mechanisms of action on the intricate signaling pathways governing IFIT1 expression and function. Ruxolitinib, a JAK inhibitor, directly targets the JAK/STAT pathway, serving as a specific tool for studying IFIT1-related cellular processes. Fludarabine indirectly inhibits IFIT1 by modulating the adenosine signaling pathway, disrupting the intricate network of signaling pathways that converge on IFIT1 expression. Sunitinib, a receptor tyrosine kinase inhibitor, indirectly influences IFIT1 by targeting the VEGF pathway, offering insights into the crosstalk between angiogenesis and IFIT1-related cellular processes. Niclosamide indirectly inhibits IFIT1 by modulating the Wnt/β-catenin signaling pathway, providing an indirect mechanism for inhibiting IFIT1-mediated responses by disrupting the intricate network of signaling pathways that converge on IFIT1 expression.
Dasatinib, Imatinib, and Ibrutinib indirectly influence IFIT1 by targeting Src, ABL, and BTK signaling pathways, respectively, offering insights into the role of these kinases in IFIT1-related cellular processes. SB203580, a p38 MAPK inhibitor, indirectly inhibits IFIT1 by disrupting the p38 MAPK signaling pathway, shedding light on the regulatory mechanisms governing IFIT1 expression. Trametinib, a MEK inhibitor affecting the MAPK pathway, indirectly influences IFIT1, providing insights into the intricate network of signaling pathways regulating IFIT1. Rapamycin indirectly inhibits IFIT1 by targeting the mTOR signaling pathway, disrupting the regulatory network of IFIT1 expression. SB202190, a selective p38 MAPK inhibitor, and MK-2206, an Akt inhibitor, indirectly inhibit IFIT1 by targeting the p38 MAPK and PI3K/Akt signaling pathways, respectively, providing valuable tools for unraveling the complexities of IFIT1-related cellular processes. These IFIT1 inhibitors offer a comprehensive toolkit for researchers aiming to dissect the regulatory networks governing IFIT1 expression and function. The diverse mechanisms of action of these chemicals provide unique insights into the intricate signaling pathways that converge on IFIT1, contributing to our understanding of the molecular events regulated by IFIT1 in various cellular contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib, a Janus kinase (JAK) inhibitor, directly influences IFIT1 by targeting the JAK/STAT pathway. By inhibiting JAK1 and JAK2, Ruxolitinib disrupts the downstream signaling cascades, including STAT1 activation. Since IFIT1 expression is induced by activated STAT1, Ruxolitinib serves as a direct inhibitor of IFIT1 by impeding the JAK/STAT signaling axis, providing a specific tool for studying IFIT1-related cellular processes. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $57.00 $200.00 | 15 | |
Fludarabine, a purine analog, indirectly inhibits IFIT1 by modulating the adenosine signaling pathway. As a purine analog, Fludarabine is incorporated into DNA during replication, leading to DNA damage and activation of the adenosine receptor pathway. Activation of adenosine receptors, in turn, influences downstream signaling events, including the regulation of IFIT1. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib, a receptor tyrosine kinase inhibitor, indirectly influences IFIT1 by targeting the vascular endothelial growth factor (VEGF) pathway. By inhibiting VEGF receptors, Sunitinib disrupts angiogenesis and downstream signaling cascades, including the regulation of IFIT1. Since IFIT1 expression can be modulated by VEGF signaling, | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide, an anthelmintic drug, indirectly inhibits IFIT1 by modulating the Wnt/β-catenin signaling pathway. By inhibiting Wnt signaling, Niclosamide influences downstream events, including the regulation of IFIT1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a BCR-ABL and Src family kinase inhibitor, indirectly influences IFIT1 by targeting the Src signaling pathway. By inhibiting Src kinases, Dasatinib disrupts downstream signaling cascades, including the regulation of IFIT1. Since IFIT1 expression can be modulated by Src signaling, Dasatinib serves as an indirect inhibitor of IFIT1 by interfering with the Src-dependent regulation of IFIT1, offering insights into the role of Src kinases in IFIT1-related cellular processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib, a BCR-ABL and c-Kit inhibitor, indirectly influences IFIT1 by targeting the ABL and c-Kit signaling pathways. By inhibiting these tyrosine kinases, Imatinib disrupts downstream signaling cascades, including the regulation of IFIT1. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, indirectly influences IFIT1 by targeting the BTK signaling pathway. By inhibiting BTK, Ibrutinib disrupts downstream signaling cascades, including the regulation of IFIT1. Since IFIT1 expression can be modulated by BTK signaling, Ibrutinib serves as an indirect inhibitor of IFIT1 by interfering with the BTK-dependent regulation of IFIT1, offering insights into the role of BTK in IFIT1-related cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that indirectly influences IFIT1 by targeting the p38 MAPK signaling pathway. By inhibiting p38 MAPK, SB203580 disrupts downstream events, including the regulation of IFIT1. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib, a MEK inhibitor affecting the MAPK pathway, indirectly influences IFIT1 by targeting the MAPK/ERK signaling pathway. By inhibiting MEK, Trametinib disrupts downstream signaling cascades, including the regulation of IFIT1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly inhibits IFIT1 by targeting the mTOR signaling pathway. By inhibiting mTOR, Rapamycin disrupts downstream events, including the regulation of IFIT1. The mTOR pathway has been implicated in the control of IFIT1 expression, and Rapamycin's impact on mTOR signaling provides an indirect mechanism for inhibiting IFIT1-mediated responses by disrupting the intricate network of signaling pathways that converge on IFIT1 expression. | ||||||